Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May 4:4:19.
doi: 10.1186/1758-3284-4-19.

Systemic therapy in the management of metastatic or advanced salivary gland cancers

Aymen Lagha  1 , Nesrine Chraiet, Mouna Ayadi, Sarra Krimi, Bassem Allani, Hela Rifi, Henda Raies, Amel Mezlini
Affiliations
Review

Systemic therapy in the management of metastatic or advanced salivary gland cancers

Aymen Lagha et al. Head Neck Oncol. .

Expression of concern in

  • Comment: Head and Neck Oncology.
    BioMed Central. BioMed Central. BMC Med. 2014 Feb 5;12:24. doi: 10.1186/1741-7015-12-24. BMC Med. 2014. PMID: 24499430 Free PMC article. Review.

Abstract

Salivary gland cancers are very rare tumors. They are characterized by a histologic heterogeneity and a poor outcome. According to this rarity, few prospective data are available to date. No standard recommendations could be held for the use of systemic therapy in these tumors. Several case reports and small studies have investigated the contribution of different agents of chemotherapy. With the extension of molecular biology approach in oncology several signaling pathways have been discovered in different cancers including salivary gland cancers; thus a number of targeted therapies have been investigated. This paper reviewed exhaustively the studies investigating the role of systemic therapies (chemotherapy, targeted therapy, hormone therapy) in salivary gland cancers.

PubMed Disclaimer

References

    1. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24:2673–2678. doi: 10.1200/JCO.2005.05.3025. - DOI - PubMed
    1. Guzzo M, Locati LD, Prott FJ. et al.Major and minor salivary gland tumors. Critical reviews in Oncology/Hematology. 2010;74:134–148. doi: 10.1016/j.critrevonc.2009.10.004. - DOI - PubMed
    1. Barnes L, Eveson JW, Reichart P, Sidransky D, editor. Pathology and Genetics of Head and Neck Tumours. World Health Organization, Lyon; 2005. 3-Tumours of the Salivary Glands; p. 209.
    1. Sung MW, Kim KH, Kim JW. et al.Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003;129:1193–1197. doi: 10.1001/archotol.129.11.1193. - DOI - PubMed
    1. Laurie SA. HO AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands : a systematic review. Lancet Oncol. 2011;12:815–824. doi: 10.1016/S1470-2045(10)70245-X. - DOI - PubMed

MeSH terms

Substances